The combination of TP53INP1, TP53INP2 and AXIN2: potential biomarkers in papillary thyroid carcinoma

Endocrine

Volumn 48, Issue 2, 2015, Pages 712-717

  He, Mengzi ^a   Zhao, Yinlong ^a,b   Yi, Heqing ^c   Sun, Hui ^d   Liu, Xiaodong ^a,e   Ma, Shumei ^a  

^a Center for Radiological Research   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d JILIN UNIVERSITY   (China)

^e THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA3 INTEGRIN; AXIN; AXIN2 PROTEIN, HUMAN; CARRIER PROTEIN; HEAT SHOCK PROTEIN; ITGA3 PROTEIN, HUMAN; NUCLEAR PROTEIN; TP53INP1 PROTEIN, HUMAN; TP53INP2 PROTEIN, HUMAN; TUMOR MARKER;

BLOOD; CARCINOMA; GENE EXPRESSION; HUMAN; PHYSIOLOGY; THYROID TUMOR;

AXIN PROTEIN; BIOMARKERS, TUMOR; CARCINOMA; CARRIER PROTEINS; GENE EXPRESSION; HEAT-SHOCK PROTEINS; HUMANS; INTEGRIN ALPHA3; NUCLEAR PROTEINS; THYROID NEOPLASMS;

EID: 84938894361     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0341-8     Document Type: Letter

References (19)

1. A.Y. Chen, A. Jemal, E.M. Ward, Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 115(16), 3801 (2009)
2. X. Liu, M. He, Y. Hou, B. Liang, L. Zhao, S. Ma et al., Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma. Oncol. Rep. 29(4), 1415 (2013)
3. D. Taieb, S. Giusiano, F. Sebag, M. Marcy, C. de Micco, F.F. Palazzo et al., Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery? World J. Surg. 34(4), 830 (2010)
4. B.G. Baumgartner, M. Orpinell, J. Duran, V. Ribas, H.E. Burghardt, D. Bach et al., Identification of a novel modulator of thyroid hormone receptor-mediated action. PLoS One 2(11), e1183 (2007)
5. T.A. Haj-Ahmad, M.A. Abdalla, Y. Haj-Ahmad, Potential urinary protein biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J. Cancer 5(2), 103 (2014)
6. Z.Q. Wu, T. Brabletz, E. Fearon, A.L. Willis, C.Y. Hu, X.Y. Li et al., Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc. Natl. Acad. Sci. U.S.A. 109(28), 11312 (2012)
7. T. Shirakihara, T. Kawasaki, A. Fukagawa, K. Semba, R. Sakai, K. Miyazono et al., Identification of integrin alpha3 as a molecular marker of cells undergoing epithelial–mesenchymal transition and of cancer cells with aggressive phenotypes. Cancer Sci. 104(9), 1189 (2013)
8. G.J. Gordon, R.V. Jensen, L.L. Hsiao, S.R. Gullans, J.E. Blumenstock, S. Ramaswamy et al., Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 62(17), 4963 (2002)
9. K.H. Zou, A.J. O’Malley, L. Mauri, Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 115(5), 654 (2007)
10. T.A. Lasko, J.G. Bhagwat, K.H. Zou, L. Ohno-Machado, The use of receiver operating characteristic curves in biomedical informatics. J. Biomed. Inform. 38(5), 404 (2005)
11. C. Wang, L.M. Crapo, The epidemiology of thyroid disease and implications for screening. Endocrinol. Metab. Clin. N. Am. 26(1), 189 (1997)
12. H. Gharib, Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr. Pract. 10(1), 31 (2004)
13. N.B. Prasad, H. Somervell, R.P. Tufano, A.P. Dackiw, M.R. Marohn, J.A. Califano et al., Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin. cancer Res. 14(11), 3327 (2008)
14. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167 (2009)
15. A. Guerra, V. Marotta, M. Deandrea, M. Motta, P.P. Limone, A. Caleo et al., BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma. Endocrine 44(1), 165 (2013)
16. Di Benedetto G., Thyroid fine-needle aspiration: the relevance of BRAF mutation testing. Endocrine. 2014. doi:10.1007/s12020-014-0222-1
17. Seo J.Y, Kim E.K, Kwak J.Y, Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with “suspicious for malignant” cytology alone even when the nodules do not show suspicious US features. Endocrine. 2014. doi:10.1007/s12020-013-0150-5
18. A. Guerra, V. Di Stasi, P. Zeppa, A. Faggiano, V. Marotta, M. Vitale, BRAF (V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto’s thyroiditis is a reliable assay. Endocrine 45(2), 249 (2014)
19. E. Puxeddu, S. Filetti, BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice? Endocrine 45(3), 341 (2014)